Parkinsonian Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The algorithm includes baseline clinical and cognitive assessment, blood examination, and magnetic resonance imaging with exclusionary and inclusionary roles; dopamine transporter single-photon emission computed tomography (if no/unclear parkinsonism) or metaiodobenzylguanidine cardiac scintigraphy for suspected dementia with Lewy bodies with clear parkinsonism (round VII, votes (yes-no-abstained): 3-1-1); <sup>18</sup> F-fluorodeoxyglucose positron emission tomography for suspected frontotemporal lobar degeneration and low diagnostic confidence of Alzheimer's disease (round VII, 4-0-1); cerebrospinal fluid for suspected Alzheimer's disease (round IV, 4-1-0); and amyloid positron emission tomography if cerebrospinal fluid was not possible/accepted (round V, 4-1-0) or inconclusive (round VI, 5-0-0).
|
31692118 |
2020 |
Parkinsonian Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The objective of this study was to report long-lasting effects of bupropion on brain dopamine transporter (DAT) in a patient with depression and parkinsonism.
|
31361666 |
2020 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Dopamine transporter (DAT) imaging is an important adjunct in the diagnostic workup of patients with Parkinsonism.
|
31776633 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Dopamine transporter (DAT) imaging such as <sup>123</sup>I-ioflupane (<sup>123</sup>I-FP-CIT) SPECT is a useful tool for the diagnosis of parkinsonism and dementia.
|
31140153 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Twenty one out of the 25 DAT scans proved the clinical diagnosis of degenerative parkinsonism to be correct.
|
29133699 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Studies using the clinical diagnosis of a movement disorders specialist over the course of the disease as a reference have shown that DAT- SPECT is 78-100% sensitive (median, 93%) and 70-100% specific (median, 89%) for the differentiation of neurodegenerative parkinsonian syndromes from symptomatic parkinsonism and other differential diagnoses in clinically unclear cases.
|
31774054 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent developments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valbenazine and deutetrabenazine, the first drugs indicated for tardive syndromes, have improved outcomes for many patients with drug-induced movement disorders.
|
31279747 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Dopamine transporter (DAT) single-photon emission tomography (SPECT) with (123)Ioflupane is a widely used diagnostic tool for patients with suspected parkinsonian syndromes, as it assists with differentiating between Parkinson's disease (PD) or atypical parkinsonisms and conditions without a presynaptic dopaminergic deficit such as essential tremor, vascular and drug-induced parkinsonisms.
|
31405186 |
2019 |
Parkinsonian Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Present data suggest that A. blazei extract plays a crucial role in regulation of proteins expression such as DAT and VMAT2 and pro-apoptotic and anti-apoptotic in Parkinsonism.
|
30468634 |
2019 |
Parkinsonian Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Diagnosis remained stable in most individuals with early parkinsonism diagnosed with iPD and with abnormal DAT imaging.
|
30958313 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Dopamine transporter imaging is a promising tool in differentiating presynaptic parkinsonism and VaP.
|
31773419 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
NMSs and their correlations with striatal DAT binding were investigated in PD patients and in parkinsonism/tremor patients with normal dopamine function.
|
31374410 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The DAT availability in other striatal subregions, including the posterior putamen, did not differ between the ADCI with parkinsonism and healthy control groups.
|
30980099 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This information can be used as a factor when the clinical need of auxiliary investigations, such as DAT SPECT, is considered for patients with parkinsonism.
|
30687897 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Concurrent impairment of Corsi span and semantic verbal fluency, or of temporal lobe hypometabolism at baseline and reduced putamen-to-caudate ratio on DAT-SPECT at parkinsonism onset, both predicted (p < 0.001) the evolution to dementia.
|
30611093 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Initial diagnostic workup of parkinsonism: Dopamine transporter positron emission tomography versus susceptibility map-weighted imaging at 3T.
|
30580909 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Patients with CO intoxication were demonstrated to exhibit white matter (WM) injuries, changes in substantia nigra, dopamine transporter dysfunctions of striatum and Parkinsonism symptoms.
|
30143836 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Tc-TRODAT-1, as a tropane-derived compound with highly selective binding to the dopamine transporter, has been extensively used as an in vivo biomarker to evaluate parkinsonism.
|
31058689 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
For these reasons, DAT SPECT has been also used as a tool to study genetic conditions that are associated with parkinsonism in order to examine the degree and patterns of dopaminergic deficits that are present in at risk subjects and in affected patients carrying the mutations.
|
30409254 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neurologists who request DAT SPECT scans are not always aware that the high accuracy is limited only to the differentiation between neurodegenerative and non-neurodegenerative parkinsonism.
|
31342202 |
2019 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We sought to assess the machine learning-based combined diagnostic accuracy of three types of quantitative indices obtained using dopamine transporter single-photon emission computed tomography (DAT SPECT)-specific binding ratio (SBR), putamen-to-caudate ratio (PCR)/fractal dimension (FD), and asymmetry index (AI)-for parkinsonian syndrome (PS).
|
30689072 |
2019 |
Parkinsonian Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
<sup>18</sup>F-FP-CIT dopamine transporter PET findings in cirrhotic patients with parkinsonism.
|
28259768 |
2018 |
Parkinsonian Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
PET with FE-PE2I revealed significant differences between patients with a clinical de novo diagnosis of PS and healthy controls in striatal DAT availability (p < 0.001), with excellent accuracy of predicting dopaminergic deficit in early-stage PS.
|
30443684 |
2018 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Scans without evidence of dopaminergic deficit (SWEDD) is a radiological nomenclature which refers to patients with a normal dopamine transporter scan presumed to have parkinsonism.
|
30072245 |
2018 |
Parkinsonian Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism.
|
30153144 |
2018 |